Clear Cell Carcinoma clinical trials at UCSF

1 in progress, 0 open to eligible people

XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Sorry, in progress, not accepting new patients
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
San Francisco, California and other locations

Last updated: February 6, 2025